U S Physical Therapy INC /NV

U.S. Physical Therapy, Inc. announced the acquisition of a twelve-clinic physical therapy practice, effective July 1, 2026, expanding its national footprint.

U.S. Physical Therapy, Inc. shareholders approved director elections, executive compensation, and auditor ratification at the May 19, 2026 Annual Meeting.

U.S. Physical Therapy, Inc. hosted a conference call to discuss its first quarter 2026 results, reporting revenue growth and reaffirming full-year guidance.

U.S. Physical Therapy, Inc. announced record first quarter revenue of $198.3 million, a 7.9% increase year-over-year, while reaffirming full-year guidance.

U.S. Physical Therapy, Inc. has entered into a new $450 million, five-year credit agreement to refinance existing debt and support future growth.

U.S. Physical Therapy, Inc. announces new objective and discretionary incentive plans for senior management for 2026, linking compensation to corporate performance and strategic goals.

U.S. Physical Therapy reports Q1 2026 net revenue of $198.3 million, up 7.9% year-over-year, despite a decline in net income attributable to shareholders.

U.S. Physical Therapy, Inc. announced significant revenue and profit increases for the third quarter and first nine months of 2025, driven by strategic acquisitions and higher patient volumes.

U.S. Physical Therapy, Inc. announced significant revenue and earnings growth for the second quarter and first half of 2025, driven by strategic acquisitions and increased patient visits.

U.S. Physical Therapy, Inc. announces a robust first quarter for 2025, marked by revenue growth from strategic acquisitions and improved patient service rates.

U.S. Physical Therapy, Inc. announced its third-quarter results, showing a decrease in net income attributable to USPH shareholders, impacted by clinic closures, while also reporting growth in revenue and adjusted EBITDA.

U.S. Physical Therapy saw a revenue increase in the second quarter of 2024, but faced challenges with gross profit margins and increased operating costs.

U.S. Physical Therapy, Inc. reported significant revenue and profit growth in 2025, driven by strategic acquisitions and an expanding clinic network, alongside a dividend increase and new hospital alliances.

U.S. Physical Therapy, Inc. announces its financial results for the year ended December 31, 2024, highlighting revenue growth, strategic acquisitions, and an increased dividend.

U.S. Physical Therapy, Inc. reports a 9.3% increase in total net revenue for 2023, driven by clinic additions and increased patient volume, while also facing challenges from Medicare reimbursement rate decreases.

Director Peter Minan acquired 780 shares of U.S. Physical Therapy, Inc. common stock through open market purchases.

Director Regg E. Swanson filed an amendment to correct the reported transaction price of a restricted stock grant.

Director Anne Motsenbocker filed an amendment to correct the reported transaction price of a restricted stock grant from $61.61 to $0.00.

Director Peter Francis Minan filed an amendment to correct the reported transaction price of a restricted stock grant from $61.61 to $0.00.

Director Kathleen A. Gilmartin filed an amendment to correct the reported transaction price of a restricted stock grant.

Anne Motsenbocker, a Director at U.S. Physical Therapy Inc., acquired 2,306 shares of common stock on May 19, 2026, as part of a restricted stock grant.

U.S. Physical Therapy, Inc. has issued its 2026 proxy statement detailing director elections, executive compensation, and the ratification of its independent auditor.

U.S. Physical Therapy, Inc. will hold its 2025 Annual Meeting of Stockholders on May 20, 2025, with key proposals including the election of directors, an advisory vote on executive compensation, and ratification of the independent auditor appointment.

U.S. Physical Therapy sets date for its annual stockholders meeting, outlining key proposals and board recommendations.

Copeland Capital Management, LLC has increased its beneficial ownership of U.S. Physical Therapy Inc. common stock to 5.53%, holding 841,544 shares.

Copeland Capital Management has filed a Schedule 13G reporting a 5.5% beneficial ownership stake in U.S. Physical Therapy, Inc.

Investment adviser Bahl & Gaynor, Inc. has filed a Schedule 13G reporting a 5.1% beneficial ownership stake in U.S. Physical Therapy, Inc.

Vanguard Capital Management has reported beneficial ownership of 777,590 shares, representing 5.14% of the outstanding common stock of US Physical Therapy Inc.

The Vanguard Group reports 0% beneficial ownership in US Physical Therapy Inc. following an internal realignment.

Copeland Capital Management, LLC has reported a 5.17% beneficial ownership stake in U S Physical Therapy Inc., holding 786,114 shares of common stock.